71 installs, hit India's top-grossing chart: a face-scanning heart-rate app, and the Singapore app portfolio behind it

PulseTrack is a Google Play health app that uses the front camera to scan your face and estimate heart rate and stress. It's been live for three weeks, has only 71 installs worldwide, and yet in Nov 6 it squeezed into No. 48 on India's "Health & Fitness" top-grossing chart. That ranking is real, but it doesn't mean the app has taken off. It only shows that India's top-grossing chart has a low bar and its subscription is expensive. What's actually worth watching is how the company behind it uses one subscription shell to swap data sources across two platforms, and the "scan your face for vitals" category that suddenly got crowded this year.

One bad review, and a face-scanning app that claims to "collect no data"

In Nov 4, a South African user left a one-star review on PulseTrack's store page:

"Useless, a waste of time and money. It doesn't work at all, it keeps pretending to say 'insufficient data'."

The next day, an Indian user added: "It isn't totally free, they do charge you."

These two are the only recent reviews visible on its store page, yet the page header shows 4.6 stars and 18 reviews (Google Play, 11-06). With 71 installs and 18 reviews, nearly a quarter of users left a rating, while a normal app sits at 1%–2%. Bad reviews mixed in with high ratings are commonly explained by the first batch of ratings being filled by friends or test accounts at launch (inference, unverified).

One more detail: this app, which has you face the camera for a few dozen seconds, states in its store-page data safety section that it "collects no data and does not share it with third parties" (Google Play, 11-06).

What it is

Open the app, hold your face to the front camera for a few dozen seconds, and it gives you pulse, HRV (heart rate variability), breathing rate, and stress level, plus a "facial skin age," with 7-day and 30-day trend charts. The technique is rPPG: reading pulse from subtle color changes in facial skin. The store page says "optical imaging with AI-assisted analysis," and the homepage says "not a medical device."

Free to download, no ads, individual in-app purchases $9.99–$39.99. Listed on 2026-10-16, updated to 11-04 as of 3.0.2.

The developer is CORELOOP PTE. LTD., a small company incorporated in Singapore in 2025 August. It also has an iOS app called PulseTrack, but that's a different product: it reads Apple Watch and Apple Health data to chart heart-rate trends (App Store, listed 2026-07, no US-store ratings yet). Android has no Apple Watch data to read, so it switched to the face scan.

What the No. 48 chart spot actually means

On the same day, on India's Health & Fitness top-grossing chart, No. 47 was TapSuite's Heart Rate Monitor (122k installs), No. 45 was Macroh with only 29k installs, and No. 55 was LooksIQ at 32k (Google Play chart, 11-06). On India's category top-grossing chart, positions 40–50 need only a few dozen dollars of revenue a day (estimate). PulseTrack needed just a few users out of a $9.99,71 minimum one-time purchase to pay to push it up.

So what it shows is that "some people will pay $10+ to measure heart rate by face scan," not "it is making money." It appeared on only one day, on one chart, and there's no growth curve to look at. Searching its name on TikTok returns no videos, nobody has mentioned it on X in the past two months, and there is no media coverage.

Who's behind it: prove it on iOS first, then move the paywall to Android

CORELOOP's website lists 5 apps: PulseTrack, Avela: Sleep Reflection (not yet listed, "30-second body scan"), Rock Sleep, OakWell, and SweepClean (a cleaning utility). The support email is gmail, the registered address is a public housing unit, and the website lists a shared-office address. It looks like a small team going global through a Singapore entity (inference).

What actually makes money is OakWell: Health Guard on iOS: listed 2026-01-06, with 3,739 ratings on the US store averaging 4.6 stars (App Store, 11-06). Third-party site ScreensDesign estimates its monthly revenue at about $15k, and AppGoblin estimates 257k cumulative installs (both estimates). It ranks between No. 50 and 200 on health top-grossing charts across a dozen-plus small countries like Colombia, Israel, Argentina, and Slovenia. Each market adds a little, and together they make a business. One App Store reviewer wrote: "The ad said it tests all your vitals for free, but it only logs sleep, and it's inaccurate." Users come in through ads.

Put these together and PulseTrack's origin is clear: the same health subscription shell and the same $9.99–$39.99 pricing, reading watch data on iOS and switching to face scanning on Android. Test the paywall first in markets with cheap acquisition like India and South Africa, and only move into expensive markets once it proves out (inference).

Who it's competing with: this year's Android face-scan apps are already crowded

PulseTrack is virtually indistinguishable from Calmia in features, copy, and pricing. Either it copied, or the two used the same white-label solution (inference). It's the latest entrant and the smallest in this category.

Calmia's review section shows what this business really looks like. In Oct 16, a one-star review that 18 people marked "helpful" said: "The fine print on the paywall doesn't match the billing described on the previous page. I took a screenshot. Straight-up scam app." In Oct 19, an Indonesian user wrote: "The ad said free for a week, but a week costs 18,000 rupiah (about $1.1). The ad also said it can check your liver. A photo tells you everything? A scam. I bought it 15 minutes ago, how do I get a refund?" The developer replied to every review with the same message: pricing was stated before payment, it's for health reference only, and refunds go through Google Play (Google Play, 11-06).

In short: the money is there. Calmia gained 27k installs in a single week, driven by paid ads and a "first-week discount" subscription. The costs are inaccurate readings, "scam" reviews, and Google Play tightening its review of health claims and subscription transparency.

If it were you

C: worth learning from, not worth following.

Five or six companies are already buying ads in the Android face-scan vitals category, and PulseTrack is still cold-starting with no differentiation. Adding a seventh copy means betting on your ad budget and your tolerance for bad reviews and takedown risk. What's worth taking is CORELOOP's playbook, not this category.

Who it fits: small teams that already run a subscription paywall, buy Google App Campaigns or Meta ads, and have a health or utility subscription app that works on iOS and want to test Android cheaply.

Who it doesn't fit: anyone hoping to stand out on accuracy (rPPG on a phone's front camera is unstable indoors, and both Calmia's and PulseTrack's bad reviews are about inaccuracy); anyone who won't buy ads and is counting on organic store traffic (PulseTrack has 71 installs after three weeks, and a generic-keyword title won't get organic reach); anyone who can't afford refunds and support.

How to do it: copy its two steps. First, one subscription shell that swaps data inputs by platform: iOS reads Apple Health and watch data, and Android, with no watch data, switches to camera or manual logging, with the paywall and pricing unchanged. Second, test paywall conversion first in cheap-acquisition markets with low category top-grossing bars like India, South Africa, and Indonesia, then move to Europe and the US once you have paid conversion. If you must build a face-scan vitals app, don't compete with Calmia on "measures everything"; do only one or two things that are relatively reliable (resting heart rate, breathing), and state the price and renewal terms on the paywall clearly enough that no one will screenshot it to mock you.

How to get users: this category has no organic traffic, so you have to buy it. Write ad creative like what Calmia and OakWell users describe: "No watch needed, just scan your face to know your heart rate and stress." But lines like "free," "checks your liver," or "measures blood pressure" turn straight into one-star reviews and refunds, and can also trigger store review.

Deadline: There's no holiday window, but the category is getting crowded. Calmia launched in April, FaceVital in June, PulseTrack in October. Three or four copycats in half a year. If you're going to test this, get results before Q1 2027, because paid acquisition only gets more expensive after that (inferred).

Read it wrong? ① PulseTrack reached tens of thousands of installs and charted in several countries' Top Grossing within 30 days. That means CORELOOP's playbook is more replicable than it looks, so bump it up. ② On the flip side, if Calmia or FaceVital got pulled from Google Play or forced to drop their health claims, the window for this category is closing, and face-scan is a risky path. ③ OakWell's iOS Top Grossing rank keeps sliding, which means even its parent's subscription playbook is getting harder.

Data and sources

• PulseTrack: Google Play store page (India store, 11-06): ratings, review text, in-app prices, data safety statement, version and release dates; India Health & Fitness Top Grossing (11-06).
• Installs, install growth, and chart ranks for similar apps: Google Play, 11-06. Calmia's review text comes from its store page (11-06).
• CORELOOP: Singapore company registry (companieshouse.sg), website coreloop.pro. iOS versions of PulseTrack and OakWell: App Store lookup (11-06).
• OakWell revenue and installs: third-party estimates from ScreensDesign and AppGoblin, unverified.
• Ads: Meta Ad Library and TikTok Ad Library (Europe) show no active ads for PulseTrack, OakWell, or Calmia. Not finding them doesn't mean they aren't running. The paid acquisition judgment comes from ad content mentioned in user reviews, so it's an inference.